NCT07502560 is a Phase 4 clinical trial of Recombinant zoster vaccine in Herpes Zoster, sponsored by GlaxoSmithKline.

Who is sponsoring NCT07502560?

NCT07502560 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT07502560?

Interventions in NCT07502560: Recombinant zoster vaccine, Placebo.

What condition does NCT07502560 study?

NCT07502560 studies Herpes Zoster.

Is NCT07502560 still recruiting?

NCT07502560 is currently not yet recruiting. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT07502560

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Not yet recruiting Phase 4 Last updated 31 March 2026

What this trial tests

Phase 4 trial testing Recombinant zoster vaccine in Herpes Zoster in 33,609 participants. Not yet recruiting.

Timeline

31 March 2026

Primary endpoint
29 March 2030

31 March 2037

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	33,609
Start date	31 March 2026
Primary completion	29 March 2030
Estimated completion	31 March 2037

Drugs / interventions tested

Recombinant zoster vaccine — full drug profile →
Placebo

Conditions studied

Herpes Zoster — all drugs for Herpes Zoster →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

76 and older, any sex, with Herpes Zoster. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Recombinant zoster vaccine

Trials testing the same drug.

NCT04516408 — Recombinant Zoster Vaccine in Stable SLE Patients · NA · unknown

Other recruiting trials for Herpes Zoster

Currently open trials in the same condition.

NCT07400003 — Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine · Phase 1, PHASE2 · recruiting
NCT07307170 — The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster · NA · recruiting
NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
NCT07361796 — The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes · NA · recruiting
NCT07378046 — The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07502560 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07502560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing